Enduring Material

- https://u.pcloud.link/publink/show?code=XZpIy80Zqgg416e8op87Hf7PTwi7BR8o0ewV

• Recognize the use of PGx to decrease the risk of inefficacy.
• Recognize the use of PGx to decrease the risk of adverse drug reactions.
• Identify resources of evidence-based PGx information/guidelines.

• Bon Secours Mercy Health Center for Continuing Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Bon Secours Mercy Health Center for Continuing Education designates this enduring material for a maximum of 1 Hour(s) NCPD (ANCC Contact Hours).
• Bon Secours Mercy Health Center for Continuing Education designates this enduring material for a maximum of 1 Credit(s) IPCE.
• Bon Secours Mercy Health Center for Continuing Education designates this enduring material for a maximum of 1 Hour(s) ACPE.
• Bon Secours Mercy Health Center for Continuing Education designates this enduring material for a maximum of 1 Hour(s) Attendance w/ No Credit.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

David Kisor, PharmD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Lets Get Checked - Consulting - Relationship Ended
• Genemarkers LLC - Consulting - Relationship Has Not Ended
• Capital Rx - Consulting - Relationship Has Not Ended
• Aura Genetics - Consulting - Relationship Ended

Any financial relationship that was found to be relevant has been mitigated.

Dylan Galford, BSN and Kenneth Nekl, MD have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

David Kisor, PharmD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Lets Get Checked - Consulting - Relationship Ended
• Genemarkers LLC - Consulting - Relationship Has Not Ended
• Capital Rx - Consulting - Relationship Has Not Ended
• Aura Genetics - Consulting - Relationship Ended

Any financial relationship that was found to be relevant has been mitigated.

This activity is not commercially supported.

70 %

100 %

4/12/2024